{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:47:24Z","timestamp":1790668044187,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006504","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T00:00:00Z","timestamp":1331683200000}}],"reference-count":116,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006504.pub2","type":"journal-article","created":{"date-parts":[[2012,3,9]],"date-time":"2012-03-09T15:48:01Z","timestamp":1331308081000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease"],"prefix":"10.1002","volume":"2014","author":[{"given":"Michal","family":"Rolinski","sequence":"first","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences; Level 6, West Wing John Radcliffe Hospital Oxford UK OX3 9DU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Fox","sequence":"additional","affiliation":[{"name":"Norwich Medical School; University of East Anglia Norwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Maidment","sequence":"additional","affiliation":[{"name":"Kent and Medway NHS and Social Care Partnership Trust; Pharmacy Department; St Martin's Hospital Littlebourne Road Canterbury Kent UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"McShane","sequence":"additional","affiliation":[{"name":"University of Oxford; Radcliffe Department of Medicine; John Radcliffe Hospital Level 4, Main Hospital, Room 4401C Oxford Oxfordshire UK OX3 9DU"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,14]]},"reference":[{"key":"10.1002\/14651858.CD006504.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","article-title":"Donepezil for cognitive impairment in Parkinson's disease: a randomized control trial","volume":"72","author":"Aarsland","year":"2002","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Dubois B Tolosa E Kulisevsky J Reichman H Jones R Burn D Efficacy and safety of donepezil in the treatment of Parkinson's disease patients with dementia Alzheimer's and Parkinson's Disease Congress, Salzburg 2007","DOI":"10.1037\/e698632007-001"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0004|cit3","unstructured":"Burn D Emre M McKeith I Reponse to rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease (EXPRESS study group) 57th Annual meeting American Academy of Neurology April 2005"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0003|cit4","doi-asserted-by":"crossref","unstructured":"Burn D Emre M McKeith I De Deyn PP Aarsland D Hsu C Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease Movement Disorders 2006 1899 907","DOI":"10.1002\/mds.21077"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Dujardin K Devos D Duhem S Destee A Marie R-M Durif F Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease Journal of Neurology 2006 1154 9","DOI":"10.1007\/s00415-006-0175-2"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0197-4580(04)80062-9","article-title":"Benefits of rivastigmine in Parkinson's disease dementia: Results from the EXPRESS study","volume":"25 Suppl 2","author":"Emre","year":"2004","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0008|cit8","unstructured":"Lees AJ An extension study to investigate the effect of Exelon (rivastigmine) on Parkinson's disease dementia National Research Register 2003"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0009|cit9","unstructured":"Olin JT Aarsland D Meng X Rivastigmine in the treatment of dementia associated with Parkinson's disease (PDD): subscale analysis of activities of daily living (ADL) Annals of Neurology. Conference: 134th American Neurological Association, ANA Meeting Baltimore, MD United States. October 2009. Conference Publication 2009 S45"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Olin JT Aarsland D Meng X Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living Dementia and Geriatric Cognitive Disorders 2010 510 5","DOI":"10.1159\/000305100"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0011|cit11","unstructured":"Poewe W EXPRESS Study Group Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An open-label extension study 57th Annual Meeting of the American Academy of Neurology, Miami Beach April 2005"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Schmitt F A Aarsland D Bronnick K S Xiangyi Meng Tekin S Evaluating rivastigmine in mild-to-moderate Parkinsons disease dementia using ADAS-cog items American Journal of Alzheimer's Disease and other Dementias 2010 407 13","DOI":"10.1177\/1533317510367486"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0013|cit13","unstructured":"Schmitt F Farlow M Olin J Effects of rivastigmine on executive function in parkinson's disease dementia: Results from a 24-week placebo-controlled clinical trial Annals of Neurology. Conference: 134th American Neurological Association, ANA Meeting Baltimore, MD United States. October 2009. Conference Publication 2009 48"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0014|cit14","unstructured":"Schmitt FA Aarsland D Bronnick KS Olin JT Meng X Evaluating cognitive effects of oral rivastigmine using subscales and items of the ADAS-cog in patients with mild to moderate Parkinson's disease dementia American Journal of Geriatric Psychiatry. Conference: 2010 AAGP Annual Meeting Savannah, GA United States. March 2010. Conference Publication 2010 79"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0015|cit15","unstructured":"Schmitt FA Aarsland DAG Bronnick KS Olin JT Meng X Evaluating cognitive effects of oral rivastigmine using subscales and items of the Adas-Cog in patients with mild to moderate Parkinson's disease dementia Neurology 2010 A270"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Schmitt FA Farlow MR Meng X Tekin S Olin JT Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia CNS Neuroscience & Therapeutics 2010 330 6","DOI":"10.1111\/j.1755-5949.2010.00182.x"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000184517.69816.e9","article-title":"Benefits of rivastigmine on attention in dementia associated with Parkinson disease","volume":"65","author":"Wesnes","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006504.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gps.993","article-title":"Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease","volume":"19","author":"Leroi","year":"2004","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0019|cit19","unstructured":"Byrne J Treatment of Lewy body dementia with Exelon National Research Register 2000 http:\/\/www.update-software.com\/NRR"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0021|cit20","unstructured":"Del Ser T Efficacy of cholinesterase inhibitors in lewy body dementia Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 5-8 April 2000, Stockholm, Sweden 2000 51"},{"issue":"11","key":"10.1002\/14651858.CD006504.pub2-BIB0020|cit21","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/1099-1166(200011)15:11<1034::AID-GPS231>3.0.CO;2-5","article-title":"Dementia with Lewy bodies: findings from an international multicentre study","volume":"15","author":"Ser","year":"2000","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0022|cit22","unstructured":"McKeith I Del Ser T Anand R Rivastigmine provides symptomatic benefit in dementia with Lewy bodies: findings from a placebo-controlled international multicenter study Neurology 2000e A450"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"McKeith I Del Ser T Spano P Emre M Wesnes K Anand R Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study Lancet 2000f 2031 6","DOI":"10.1016\/S0140-6736(00)03399-7"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0024|cit24","unstructured":"Rossor MN A prospective, multicentre, randomised double blind placebo controlled exploratory study to evaluate the safety, tolerability and efficacy of a new drug in patients suffering from probable dementia with Lewy bodies National Research Register http:\/\/www.update-software.com\/NRR 1999"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000048651","article-title":"Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the Cognitive Drug Research computerized assessment system","volume":"13","author":"Wesnes","year":"2002","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"7","key":"10.1002\/14651858.CD006504.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","article-title":"Donepezil for dementia in Parkinson's disease: a randomised, double-blind, placebo controlled, crossover study","volume":"76","author":"Ravina","year":"2005","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0028|cit27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0924-977X(02)80620-4","article-title":"Galantamine for Parkinson's disease with dementia","volume":"12 Suppl","author":"Aarsland","year":"2002","journal-title":"European Neuropsychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD006504.pub2-BIB0027|cit28","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.949","article-title":"Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia","volume":"18","author":"Aarsland","year":"2003","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0029|cit29","unstructured":"Adler G Christenn M Bektas M Ko-Inoshishi Y Kupsch A Scholz E Rivastigmine treatment in Parkinson's disease dementia: short-term cholinergic effects are correlated with six-month treatment response Alzheimer's and Dementia. Conference: Alzheimer's Association International Conference, AAIC 11 Paris France. 16-21 July 2011. Conference Publication 2011 776"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0030|cit30","unstructured":"Anand R Enz A Novartis Pharmaceuticals Corporation Effects of rivastigmine extend beyond symptomatic treatment in patients with Alzheimer's disease(AD): new clinical studies Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden 2000 29"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Barone P Burn DJ van Laar T Hsu C Poewe W Lane RM Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients Movement Disorders 2008 1532 40","DOI":"10.1002\/mds.21997"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0032|cit32","unstructured":"Barone P De Deyn P Emre M Kulisevsky J Poewe W Pourcher E Baseline data from a long-term safety study of rivastigmine capsules and patch in mild to moderate Parkinson's disease dementia Movement Disorders. Conference: 14th International Congress of Parkinson's Disease and Movement Disorders Buenos Aires Argentina. 13-17 June 2010. Conference Publication 2010 486 7"},{"issue":"2","key":"10.1002\/14651858.CD006504.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002826-200203000-00009","article-title":"Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease","volume":"25","author":"Bergman","year":"2002","journal-title":"Clinical Neuropharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006504.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00002826-200303000-00008","article-title":"Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type","volume":"26","author":"Bergman","year":"2003","journal-title":"Clinical Neuropharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006504.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00019442-200409000-00016","article-title":"Donepezil in the treatment of dementia with Lewy bodies","volume":"12","author":"Beversdorf","year":"2004","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD006504.pub2-BIB0036|cit36","first-page":"5","article-title":"A double-blind placebo-controlled trial of donepezil in patients with Parkinson's disease and related dementia","volume":"62","author":"Brashear","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Chung KA Lobb BM Nutt JG Horak FB Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease Neurology 2010 1263 9","DOI":"10.1212\/WNL.0b013e3181f6128c"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Cummings J Emre M Aarsland D Tekin S Dronamraju N Lane R Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations Journal of Alzheimer's Disease 2010 301 11","DOI":"10.3233\/JAD-2010-1362"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0039|cit39","unstructured":"De Deyn P Poewe W Barone P Emre M Kulisevsky J Pourcher E Results of a long-term safety study of rivastigmine capsules and patch in patients with mild to moderate dementia associated with Parkinson's disease Neurodegenerative Diseases. Conference: 10th International Conference AD\/PD - Alzheimer's and Parkinson's Diseases: Advances, Concepts and New Challenges Barcelona Spain. 9-13 March 2011. Conference Publication 2011"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s100720200022","article-title":"Donepezil in the treatment of hallucinations and delusions in Parkinson's disease","volume":"23","author":"Fabbrini","year":"2002","journal-title":"Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD006504.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1034\/j.1600-0404.2003.00081.x","article-title":"Effects of rivastigmine on the quantitative EEG in demented parkinsonian patients","volume":"107","author":"Fogelson","year":"2003","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0042|cit42","unstructured":"Foy C The non-dopaminergic neuropharmacology of idiopathic Parkinson's Disease Thesis submitted in fulfilment for a Doctor of Philosophy, Section of Clinical Neurology, University of Sheffield (accessed from the British Library) 2000"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0043|cit43","unstructured":"Grunewald RA Investigation of the effects of rivastigmine on cognition in Parkinson's disease National Research Register 1999"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Fujita Y Takebayash M Efficacy of low-dose donepezil for visual hallucinations in a patient with dementia with Lewy bodies Psychiatry and Clinical Neurosciences 2010 336","DOI":"10.1111\/j.1440-1819.2010.02088.x"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1034\/j.1600-0404.2003.00211.x","article-title":"Rivastigmine for dementia in patients with Parkinson's disease","volume":"108","author":"Giladi","year":"2003","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Gustavsson A Van Der Putt R Jonsson L McShane R Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies International Journal of Geriatric Psychiatry 2009 1072 8","DOI":"10.1002\/gps.2223"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jnnp.61.3.324-a","article-title":"Cholinesterase inhibition in Parkinson's disease","volume":"61","author":"Hutchinson","year":"1996","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0048|cit48","first-page":"61","article-title":"The effect of treatment with rivastigmine (Exelon) on cognitive functions of patients with dementia and Parkinson's disease","volume":"7 Suppl","author":"Korczyn","year":"2001","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/(SICI)1099-1166(200004)15:4<338::AID-GPS119>3.0.CO;2-U","article-title":"Donepezil for behavioural disorders associated with Lewy bodies: a case series","volume":"15","author":"Lanctot","year":"2000","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006504.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/01.wnf.0000172498.24770.54","article-title":"Efficacy and safety of donepezil in cognitive impairment in Parkinson's disease: a pilot study","volume":"28","author":"Linsarozo","year":"2005","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Litvinenko IV Odinak MM Mogil'naya VI Emelin AYU Efficacy and safety of galantamine (Reminyl) for dementia in patients with Parkinson's disease (an open controlled trial) Neuroscience and Behavioral Physiology 2008 937 45","DOI":"10.1007\/s11055-008-9077-3"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0052|cit52","unstructured":"McKeith IG A pilot study into the effects of donepezil on cognitive impairment and neuropsychiatric features in patients with dementia with Lewy bodies and Parkinson's disease National Research Register 2000a"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000068781","article-title":"Cardiovascular effects of donepezil in patients with dementia","volume":"15","author":"McLaren","year":"2003","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"11","key":"10.1002\/14651858.CD006504.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/gps.995","article-title":"What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia","volume":"18","author":"Minett","year":"2003","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006504.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1819.2006.01485.x","article-title":"Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study","volume":"60","author":"Mori","year":"2006","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Olin JT Bhatnagar V Reyes P Koumaras B Meng X Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: A 26-week, open-label, prospective trial (Study ENA713B US32) International Journal of Geriatric Psychiatry 2010 419 26","DOI":"10.1002\/gps.2355"},{"issue":"8","key":"10.1002\/14651858.CD006504.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/gps.1547","article-title":"Cholinesterase inhibitors in advanced dementia with Lewy bodies: increase or stop?","volume":"21","author":"Pakrasi","year":"2006","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.1204","article-title":"Rivastigmine in the treatment of Parkinson's psychosis and cognitive impairment: preliminary findings from an open trial","volume":"16","author":"Reading","year":"2001","journal-title":"Movement Disorders"},{"issue":"5","key":"10.1002\/14651858.CD006504.pub2-BIB0059|cit59","first-page":"359","article-title":"Effect of donepezil on dementia in Parkinson's disease and Alzheimer's disease: a pilot study","volume":"67","author":"Rektorova","year":"2004","journal-title":"Ceska a Slovenska Neurologie a Neurchirurgie"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0060|cit60","doi-asserted-by":"crossref","unstructured":"Rosengarten B Dannhardt V Burr O Pohler M Rosengarten S Oechsner M Neurovascular coupling in Parkinson's disease patients: effects of dementia and acetylcholinesterase inhibitor treatment Journal of Alzheimer's Disease 2010 415 21","DOI":"10.3233\/JAD-2010-101140"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Samuel W Caligiuri M Galasko D Lacro J Marini M McClure FS Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: A preliminary study International Journal of Geriatric Psychiatry 2000 794 802","DOI":"10.1002\/1099-1166(200009)15:9<794::AID-GPS178>3.0.CO;2-1"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Satoh M Ishikawa H Meguro K Kasuya M Ishii H Yamauchi S Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project European Neurology 2010 337 44","DOI":"10.1159\/000322121"},{"issue":"10","key":"10.1002\/14651858.CD006504.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/gps.1381","article-title":"A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies","volume":"20","author":"Thomas","year":"2005","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006504.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079906X80279","article-title":"Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology","volume":"22","author":"Touchon","year":"2006","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"10.1002\/14651858.CD006504.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1185\/030079906X80279","article-title":"Erratum: Response to rivastigmine or donepezil in Alheimer's patients with symptoms suggestive of concomitant Lewy body pathology","volume":"22","author":"Touchon","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0066|cit66","first-page":"73","article-title":"Rivastigmine as anti-psychotic treatment in patients with Parkinson's disease","volume":"7 Suppl","author":"Laar","year":"2001","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0067|cit67","unstructured":"Vasile D Vasiliu O Vasile ML Terpan M Grigorescu G Bogdan V Comparative efficacy of cholinesterase inhibitors in dementia associated with Parkinson's disease European Neuropsychopharmacology. Conference: 23rd European College of Neuropsychopharmacology, ECNP Congress Amsterdam, Netherlands. 28 August to 1 September 2010. Conference Publication 2010 553 4"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0068|cit68","unstructured":"Vasile D Vasiliu O Management of cognitive symptoms in dementia associated with Parkinson's disease Proceedings of the World Medical Conference 2010 284 6"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0069|cit69","unstructured":"Walker Z Lewy body dementia: The investigation of pre and post synaptic dopaminergic receptors with SPET NRR 2000 http:\/\/www.doh.gov.uk\/nrr.htm"},{"issue":"11","key":"10.1002\/14651858.CD006504.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s007020100008","article-title":"The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia","volume":"108","author":"Werber","year":"2001","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0071|cit71","unstructured":"Wilcock GK A double-blind, placebo-controlled, randomised, parallel group phase IIa study of the efficacy and safety of a novel therapy in the treatment of behavioural and psychological symptoms in subjects with dementia with Lewy bodies National Research Register 2000e"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0072|cit72","unstructured":"Anon Donepezil to treat dementia in Parkinson's disease ClinicalTrials.gov 2004"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0073|cit73","unstructured":"Anon Double-blind study of E2020 in patients with dementia with Lewy bodies - Phase II ClinicalTrials.gov 2007"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0074|cit74","unstructured":"Anon A study of E2020 in patients with dementia with Lewy bodies (DLB), followed by a long-term extension phase - Phase III ClinicalTrials.gov 2011"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0075|cit75","unstructured":"Burn DJ Multi-centre UK study of the acetylcholinesterase inhibitor donepezil in early dementia associated with Parkinson's disease (MUSTARDD-PD) ClinicalTrials.gov: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01014858 2009"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0076|cit76","unstructured":"Kuran R Treatment of agitation\/psychosis in dementia\/parkinsonism Alzheimer's Disease Education and Referral Centre (ADEAR) 2003"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0077|cit77","unstructured":"Marion MH An open 24 week prospective, randomised, double-blind placebo controlled parallel group study of efficacy, tolerability and safety of 3-12mg\/day of Exelon and Exelon (rivastigmine) capsules in patients with Parkinson's disease dementia National Research Register 2003"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.60.3.387","article-title":"Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study","volume":"60","author":"Aarsland","year":"2003","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.20527","article-title":"A systematic review of prevalence studies of dementia in Parkinson's disease","volume":"20","author":"Aarsland","year":"2005","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000249130.63615.cc","article-title":"Differences in neuropathologic characteristics across the Lewy body dementia spectrum","volume":"67(11)","author":"Ballard","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/01688639608408304","article-title":"Word-list generation deficits in dementia","volume":"18","author":"Barr","year":"1996","journal-title":"Journal of Clinical and Experimental Neuropsychology"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0082|cit82","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-59259-326-2","volume-title":"Mental and Behavioural dysfunction in movement disorders","author":"Bedard","year":"2003"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0083|cit83","volume-title":"Revised Administration, Scoring and Teaching Manual for the Developmental Test of Visual-Motor Integration","author":"Beery","year":"1989"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0084|cit84","doi-asserted-by":"crossref","unstructured":"Bostrom F Jonsson L Minthon L Londos E Patients with Lewy body dementia use more resources than those with Alzheimer's disease International Journal of Geriatric Psychiatry 2006 713 9","DOI":"10.1002\/gps.1738"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jns.2006.05.011","article-title":"Cognitive decline correlates with neuropathological stage in Parkinson's disease","volume":"248(1-2)","author":"Braak","year":"2006","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0086|cit86","volume-title":"Hopkins Verbal Learning Test-Revised, Professional Manual","author":"Brandt","year":"2001"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/mds.10566","article-title":"Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease","volume":"18 Suppl 6","author":"Burn","year":"2003","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/01.wco.0000247607.34697.a2","article-title":"Cortical Lewy body disease and Parkinson's disease dementia","volume":"19(6)","author":"Burn","year":"2006","journal-title":"Current Opinions in Neurology"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0090|cit90","volume-title":"Delis-Kaplan executive function system","author":"Delis","year":"2001"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/PL00007725","article-title":"Cognitive deficits in Parkinson's disease","volume":"244","author":"Dubois","year":"1997","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0092|cit92","first-page":"153","article-title":"Unified Parkinson's disease rating scale","volume-title":"Recent Developments in Parkinson's Disease II","author":"Fahn","year":"1987"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0094|cit94","first-page":"533","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11 Suppl 2","author":"Galasko","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0095|cit95","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch16","article-title":"Chapter 16: Special topics in statistics","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0096|cit96","first-page":"141","article-title":"Neuropathological correlates of mental dysfunction in Parkinson's disease","volume-title":"Mental Dysfunction in Parkinson's Disease","author":"Jellinger","year":"1994"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neuron.2006.09.026","article-title":"Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery","volume":"52(1)","author":"Lee","year":"2006","journal-title":"Neuron"},{"issue":"1","key":"10.1002\/14651858.CD006504.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ana.410430117","article-title":"The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease","volume":"43","author":"Lippa","year":"1998","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006504.pub2-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004747.pub2","article-title":"Cholinesterase inhibitors for Parkinson's disease dementia","author":"Maidment","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2190\/5A0F-936P-VG8N-0F5R","article-title":"The ten point clock drawing test: a quick screen and grading method for cognitive impairment in medical and surgical patients","volume":"24","author":"Manos","year":"1994","journal-title":"International Journal of Psychiatry in Medicine"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0101|cit101","volume-title":"Dementia Rating Scale (DRS) Professional Manual","author":"Mattis","year":"1988"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/bmj.305.6855.673","article-title":"Neuroleptic sensitivity in patients with senile dementia of Lewy body type","volume":"305","author":"McKeith","year":"1992","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/ana.410150503","article-title":"Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease","volume":"15","author":"Nakano","year":"1984","journal-title":"Annals of Neurology"},{"issue":"11","key":"10.1002\/14651858.CD006504.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/mds.21013","article-title":"Ubiquitin-proteasome system and Parkinson's disease","volume":"21","author":"Olanow","year":"2006","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"7","key":"10.1002\/14651858.CD006504.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/00001756-199403000-00002","article-title":"Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease","volume":"5","author":"Perry","year":"1994","journal-title":"NeuroReport"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","article-title":"Validity of the Trail Making Test as an indicator of organic brain damage","volume":"8","author":"Reitan","year":"1958","journal-title":"Perceptual and Motor Skills"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change","volume":"11 Suppl 2","author":"Schneider","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0112|cit112","volume-title":"Brief Test of Attention Professional Manual","author":"Schretlen","year":"1997"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/gps.930060208","article-title":"The cognitive assessment system for the demented patients: a validation study","volume":"6","author":"Simpson","year":"1991","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006504.pub2-BIB0114|cit114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003672","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies","author":"Wild","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006504.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/jnnp.2008.155895","article-title":"Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease","volume":"80","author":"Williams","year":"2009","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD006504.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/ageing\/afi190","article-title":"A systematic review of prevalence and incidence studies of dementia with Lewy bodies","volume":"34","author":"Zaccai","year":"2005","journal-title":"Age and Ageing"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006504.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:17:18Z","timestamp":1747109838000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006504.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,3,14]]},"references-count":116,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006504.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,14]]}}}